Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic

Osamu Sato1, Takuro Wada, Akira Kawai

  • 1Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan.

Cancer
|March 18, 2005
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) overexpression is a negative prognostic factor in adult soft tissue sarcomas (STS), linked to higher histologic grade. Patients with EGFR overexpression may benefit from targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Receptor tyrosine kinase expression in adult soft tissue sarcomas (STS) is poorly understood.
  • This study investigates the expression of epidermal growth factor receptor (EGFR), ERBB2, and KIT in adult STS.

Purpose of the Study:

  • To analyze the expression of EGFR, ERBB2, and KIT in adult STS.
  • To determine the association between the expression of these receptors and patient prognosis.

Main Methods:

  • Immunohistochemical analysis of EGFR, ERBB2, and KIT expression in 281 adult STS tissue samples.
  • Correlation of receptor expression with histologic grade and patient survival data.

Main Results:

  • EGFR overexpression was detected in 60% of patients and was common in several STS subtypes.
  • EGFR overexpression was significantly associated with a worse overall survival and higher histologic grade.
  • ERBB2 and KIT expression was very limited in the studied cohort.

Conclusions:

  • EGFR overexpression serves as a negative prognostic indicator in adult STS.
  • EGFR overexpression is strongly linked to the histologic grade of STS.
  • Adult STS patients with EGFR overexpression might respond favorably to EGFR-targeted therapies.